Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics reported third-quarter 2026 financial results and pipeline updates. It dosed the first patient in the Phase 1/2 trial of XTX501 and is advancing XTX602 and XTX701 toward planned IND applications in the fourth quarter of 2027.
Why it matters — The update provides XLO watchers with information on clinical-trial enrollment and the company’s development timelines for three pipeline programs.